Latest Content

W. Kimryn Rathmell, MD, PhD, FASCO, champions the dyad model to enhance oncology care accessibility, bridging gaps between rural patients and clinical trials.

The CEO of ModeX Therapeutics discusses MDX2003, a groundbreaking tetraspecific therapy that promises enhanced efficacy and safety in non-Hodgkin lymphoma treatment. This exchange appears in the January issue of Evidence-Based Oncology, the annual recap of the meeting of the American Society of Hematology.

The complex disparities in pancreatic cancer survival trends across demographics and regions highlight urgent needs for targeted interventions.

Filippo Pietrantonio, MD, discusses findings from the phase 1/2 OrigAMI-1 study in RAS/BRAF wild-type mCRC.

Zanidatamab shows promise in extending survival for patients with HER2-positive biliary tract cancer, marking a significant breakthrough in treatment options.

Reduced doses and shorter durations of venetoclax can enhance treatment outcomes and reduce adverse events in acute myeloid leukemia (AML).

Johnson & Johnson partners with the Trump Administration to lower drug prices and utilize TrumpRx.com, joining a growing list of pharmaceutical companies.

Patients with unresectable stage III non–small cell lung cancer (NSCLC) had previously received neoadjuvant chemoimmunotherapy.

Circulating tumor DNA shows promise in detecting esophageal cancer recurrence earlier than traditional methods, enhancing posttreatment surveillance.